Aliases & Classifications for Somatization Disorder

MalaCards integrated aliases for Somatization Disorder:

Name: Somatization Disorder 12 14 69
Polysomatising Disorder 12
Somatisation Disorder 12
Somatoform Disorders 42
Somatoform Disorder 69
Briquet's Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13918
ICD10 33 F45.0 F45 F45.9
ICD9CM 35 300.81
MeSH 42 D013001
UMLS 69 C0520482

Summaries for Somatization Disorder

Disease Ontology : 12 A somatoform disorder that involves persistently complaints of varied physical symptoms that have no identifiable physical origin.

MalaCards based summary : Somatization Disorder, also known as polysomatising disorder, is related to somatoform disorder and personality disorder, and has symptoms including multiple somatic complaints An important gene associated with Somatization Disorder is DCXR (Dicarbonyl And L-Xylulose Reductase), and among its related pathways/superpathways are Jak-STAT signaling pathway (KEGG) and Signaling pathways regulating pluripotency of stem cells. The drugs Dopamine and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include testes, pituitary and brain, and related phenotype is Increased HDAC inhibitor resistance.

Wikipedia : 72 Somatization disorder (also Briquet\'s syndrome) is a mental disorder characterized by recurring,... more...

Related Diseases for Somatization Disorder

Graphical network of the top 20 diseases related to Somatization Disorder:



Diseases related to Somatization Disorder

Symptoms & Phenotypes for Somatization Disorder

UMLS symptoms related to Somatization Disorder:


multiple somatic complaints

GenomeRNAi Phenotypes related to Somatization Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased HDAC inhibitor resistance GR00115-A-0 8.62 LIF LIFR

Drugs & Therapeutics for Somatization Disorder

Drugs for Somatization Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
2
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
3
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
4
Fluoxetine Approved, Vet_approved Phase 4,Phase 1,Phase 2 54910-89-3 3386
5
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
6
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
7
Mianserin Approved Phase 4 24219-97-4 4184
8
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
9
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
10 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
11 Analgesics Phase 4,Phase 3
12 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Dopamine Agents Phase 4,Phase 3
14 Duloxetine Hydrochloride Phase 4,Phase 3
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
17 Peripheral Nervous System Agents Phase 4,Phase 3
18
Serotonin Phase 4,Phase 3,Phase 1,Phase 2 50-67-9 5202
19 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 3
20 Adrenergic Agents Phase 4,Phase 2
21 Antidepressive Agents, Tricyclic Phase 4,Phase 2
22 Adrenergic alpha-Antagonists Phase 4
23 Adrenergic Antagonists Phase 4
24 Anti-Anxiety Agents Phase 4
25 Antidepressive Agents, Second-Generation Phase 4,Phase 1,Phase 2
26 Antimanic Agents Phase 4
27 Central Nervous System Depressants Phase 4
28 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
29 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 1,Phase 2
30 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 1,Phase 2
31 Dopamine Uptake Inhibitors Phase 4
32 Histamine Antagonists Phase 4
33 Histamine H1 Antagonists Phase 4
34
Histamine Phosphate Phase 4 51-74-1 65513
35 Lithium carbonate Phase 4 554-13-2
36 Serotonin Agents Phase 4,Phase 1,Phase 2
37 Serotonin Antagonists Phase 4
38 Serotonin Uptake Inhibitors Phase 4,Phase 1,Phase 2
39 Tranquilizing Agents Phase 4
40
Imipramine Approved Phase 2 50-49-7 3696
41
Hyoscyamine Approved 101-31-5 64692
42 Acetaminophen, hydrocodone drug combination
43 Adjuvants, Anesthesia
44 Anesthetics
45 Anti-Arrhythmia Agents
46 Anti-Asthmatic Agents
47 Autonomic Agents
48 Bronchodilator Agents
49 Cholinergic Agents
50 Cholinergic Antagonists

Interventional clinical trials:

(show all 31)

id Name Status NCT ID Phase Drugs
1 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4 Psychotropic medication optimization
2 Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression Completed NCT01754493 Phase 4 Duloxetine
3 A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder Completed NCT00960986 Phase 4 Duloxetine hydrochloride
4 Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics Recruiting NCT03219008 Phase 4 Fluoxetine;fluoxetine + Amfebutamone;Fluvoxamine;Lithium+fluvoxamine;Mirtazapine/SNRIs;mirtazapine + SNRIs
5 Treatment of Medically Unexplained Physical Ailments (Somatization Disorder) Completed NCT00050583 Phase 3
6 Treatment of Patients With Longstanding Unexplained Health Complaints Completed NCT00132197 Phase 2, Phase 3
7 Integrated Treatment Program for Hypochondriasis in Primary Care Settings Completed NCT00368212 Phase 3
8 Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder Completed NCT00105989 Phase 3 Duloxetine;placebo
9 Effectiveness of Cognitive-Affective Behavior Therapy for the Treatment of Somatization Disorder Completed NCT00149760 Phase 2
10 Cognitive Behavior Therapy for Somatization Disorder Completed NCT00276887 Phase 2
11 Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome Completed NCT01518634 Phase 2 Imipramine treatment;Placebo
12 Effects of Emotional Stimulation on the Stress Levels of Healthy Persons Completed NCT01187797 Phase 1, Phase 2
13 Hierarchical Treatment Based on Somatization Symptom Checklist Recruiting NCT02723903 Phase 1, Phase 2 Deanxit;Prozac
14 An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress Suspended NCT02498392 Phase 2 JNJ-42165279
15 Using Neuroimaging to Investigate Major Depressive Disorder Unknown status NCT00781677
16 Delivery of Self Training and Education for Stressful Situations-Telephone Version Unknown status NCT01502449
17 Effectiveness of Buddhist Monks in Providing Cognitive Behavior Therapy Unknown status NCT01706731
18 Acceptance and Commitment Therapy for Patients With Multi-organ Bodily Distress Syndrome (Stress-4) Completed NCT01518647
19 Acceptance and Commitment Group Therapy (ACT) for Patients With Health Anxiety Completed NCT01158430
20 Mindfulness-based Cognitive Therapy for Patients With Functional Disorders Completed NCT00497185
21 Supporting Primary Care in Diagnosis and Choice of Treatment for Patients With Psychosocial Symptoms: SGEPsyScan. Completed NCT01971307
22 Web-Based Survey of Pain, Stress and Complementary and Alternative Medicine Completed NCT00740233
23 Mantram Repetition to Manage PTSD in Veterans Completed NCT00120627
24 Cognitive Behavior Therapy (CBT) for Children With Functional Gastrointestinal Disorders Completed NCT02113605
25 Treating Emotional Disorders in Primary Care With Psychological Techniques Recruiting NCT01903096 Primary Care Treatment As Usual
26 Acceptance and Commitment Group Therapy for Adolescents With a Range of Functional Somatic Syndromes Recruiting NCT02346071
27 Mindfulness Therapy in Inflammatory Bowel Disease Recruiting NCT02963246
28 Study Assessing Risk Factors for Abdominal Pain in Children With Inflammatory Bowel Disease Recruiting NCT02984059
29 Efficacy of Open Label Placebo in Children With FGIDs Recruiting NCT02389998 Hyoscyamine
30 Clinical, Neurophysiological and Neuroendocrine Effects of Aerobe Exercise in Generalized Anxiety Disorder (GAD) Enrolling by invitation NCT02662803
31 Fructose Breath-testing in Irritable Bowel Syndrome (IBS) Not yet recruiting NCT02614313

Search NIH Clinical Center for Somatization Disorder

Cochrane evidence based reviews: somatoform disorders

Genetic Tests for Somatization Disorder

Anatomical Context for Somatization Disorder

MalaCards organs/tissues related to Somatization Disorder:

39
Testes, Pituitary, Brain

Publications for Somatization Disorder

Articles related to Somatization Disorder:

(show top 50) (show all 163)
id Title Authors Year
1
Somatization disorder and somatoform symptoms in systematically studied survivors of 10 disasters. ( 28738098 )
2017
2
Somatization disorder among adolescents in southeast Nigeria: a neglected issue. ( 28947913 )
2017
3
Anatomical distance affects cortical-subcortical connectivity in first-episode, drug-naive somatization disorder. ( 28411503 )
2017
4
Decreased Plasma BDNF Levels of Patients with Somatization Disorder. ( 27757131 )
2016
5
Decreased interhemispheric functional connectivity in insula and angular gyrus/supramarginal gyrus: Significant findings in first-episode, drug-naive somatization disorder. ( 26826895 )
2016
6
Abnormal default-mode network homogeneity and its correlations with personality in drug-naive somatization disorder at rest. ( 26771948 )
2016
7
Clinical significance of increased cerebellar default-mode network connectivity in resting-state patients with drug-naive somatization disorder. ( 27428190 )
2016
8
Abnormal regional homogeneity and its correlations with personality in first-episode, treatment-naive somatization disorder. ( 26026373 )
2015
9
Alterations in white matter integrity in first-episode, treatment-naive patients with somatization disorder. ( 26003450 )
2015
10
Increased functional connectivity strength of right inferior temporal gyrus in first-episode, drug-naive somatization disorder. ( 25313257 )
2014
11
Trauma-related psychiatric comorbidity of somatization disorder among women in eastern Turkey. ( 25214370 )
2014
12
SYMPTOMATOLOGY AND COMORBIDITY OF SOMATIZATION DISORDER AMONGST GENERAL OUTPATIENTS ATTENDING A FAMILY MEDICINE CLINIC IN SOUTH WEST NIGERIA. ( 26069465 )
2014
13
Dissociation of regional activity in default mode network in medication-naive, first-episode somatization disorder. ( 24983962 )
2014
14
A study of disability and its correlates in somatization disorder. ( 24655628 )
2014
15
Caregiver burden and disability in somatization disorder. ( 24119946 )
2013
16
Effectiveness of group versus individual cognitive-behavioral therapy in patients with abridged somatization disorder: a randomized controlled trial. ( 23788694 )
2013
17
Mindfulness therapy for somatization disorder and functional somatic syndromes: analysis of economic consequences alongside a randomized trial. ( 23272987 )
2013
18
Mindfulness therapy for somatization disorder and functional somatic syndromes: randomized trial with one-year follow-up. ( 23272986 )
2013
19
Brain dysfunction in fibromyalgia and somatization disorder using proton magnetic resonance spectroscopy: a controlled study. ( 22211322 )
2012
20
Pituitary volumes are reduced in patients with somatization disorder. ( 22993528 )
2012
21
Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder. ( 22475718 )
2012
22
Hippocampus and amygdalar volumes in patients with somatization disorder. ( 21651951 )
2011
23
The association between Helicobacter Pylori chronic gastritis, psychological trauma and somatization disorder. A case report. ( 21961102 )
2011
24
From traumatic attachment to somatization disorder. ( 21995353 )
2011
25
Somatization disorder treated with electroconvulsive therapy. ( 21865963 )
2011
26
Perceived social support and life satisfaction in persons with somatization disorder. ( 22174534 )
2010
27
Complex post-traumatic stress disorder in patients with somatization disorder. ( 19085532 )
2009
28
C-reactive protein variations for different chronic somatic disorders. ( 19372230 )
2009
29
Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders. ( 19906238 )
2009
30
Is baroreflex sensitivity really pathological in patients with somatization disorder? Comment on: Laederach-Hofmann et al. (2008). ( 19505528 )
2009
31
Cognitive-behaviour therapy for patients with Abridged Somatization Disorder (SSI 4,6) in primary care: a randomized, controlled study. ( 18570681 )
2008
32
Cognitive-affective neuroscience of somatization disorder and functional somatic syndromes: reconceptualizing the triad of depression-anxiety-somatic symptoms. ( 18496475 )
2008
33
Childhood maltreatment in patients with somatization disorder. ( 18330776 )
2008
34
Are patients with somatization disorder highly suggestible? ( 18028249 )
2008
35
Managing somatization disorder. ( 23212087 )
2008
36
Vulvodynia as a possible somatization disorder. More than just an opinion. ( 17393771 )
2007
37
Somatization disorder, a cause of difficult pain: a case report. ( 17601846 )
2007
38
Temperament profiles in women with somatization disorder. ( 17875043 )
2007
39
P300 endogen evoked potentials in somatization disorder: a controlled study. ( 17323226 )
2007
40
Personality disorders in somatization disorder patients: a controlled study in Spain. ( 17540225 )
2007
41
Cognitive-behavioral therapy for somatization disorder: a randomized controlled trial. ( 16864762 )
2006
42
Distinguishing between hypochondriasis and somatization disorder: a review of the existing literature. ( 16899963 )
2006
43
Dissociation, childhood interpersonal trauma, and family functioning in patients with somatization disorder. ( 15863791 )
2005
44
The presentation of irritable bowel syndrome in the context of somatization disorder. ( 15354279 )
2004
45
Somatization disorder--a defensive waste of NHS resources. ( 15103033 )
2004
46
Somatization disorder and cancer: a case history and review. ( 16594404 )
2004
47
Suicide risk in patients with somatization disorder. ( 15384650 )
2004
48
Episodic ataxia vs somatization disorder. ( 15633862 )
2004
49
Somatization disorder in young adult population. ( 14757296 )
2004
50
Volumes of the caudate nuclei in women with somatization disorder and healthy women. ( 15246456 )
2004

Variations for Somatization Disorder

Expression for Somatization Disorder

Search GEO for disease gene expression data for Somatization Disorder.

Pathways for Somatization Disorder

GO Terms for Somatization Disorder

Biological processes related to Somatization Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to cytokine GO:0034097 9.26 LIFR SCGB1A1
2 embryo implantation GO:0007566 9.16 LIF SCGB1A1
3 regulation of cell differentiation GO:0045595 8.96 LIF SIK1
4 leukemia inhibitory factor signaling pathway GO:0048861 8.62 LIF LIFR

Sources for Somatization Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....